Skip to main content
Top
Published in: Diabetologia 3/2011

Open Access 01-03-2011 | Short Communication

Cardiovascular disease, heart failure, chronic kidney disease and depression independently increase the risk of incident diabetes

Authors: G. A. Nichols, E. J. Moler

Published in: Diabetologia | Issue 3/2011

Login to get access

Abstract

Aims/hypothesis

Diabetes increases the risk of cardiovascular disease (CVD) and heart failure, as well as other serious complications, such as renal disease and depression. However, these conditions are often present prior to diabetes diagnosis. We sought to determine whether they increase the risk of developing diabetes independent of other risk factors.

Methods

We identified 58,056 non-diabetic adults aged ≥30 years with no evidence of diabetes. Using electronic medical records, we identified the presence of four conditions at baseline (CVD, heart failure, renal disease and depression) and then estimated diabetes incidence over 5 years separately for patients with and without each of these conditions. Each incidence estimate was adjusted for baseline values of age, sex, fasting glucose, body mass index, systolic blood pressure, triacylglycerol, HDL-cholesterol, smoking and the presence of the other three conditions.

Results

Patients with CVD were 35% (95% CI 23–48%) more likely to develop diabetes after controlling for other risk factors. Heart failure was independently associated with an increase in diabetes incidence of 48% (95% CI 27–73%), and depression was associated with a 10% (95% CI 2–20%) increase. Chronic kidney disease was associated with a non-significant risk increase of 10% (95% CI –2–25%).

Conclusions/interpretation

Complications of diabetes are more prevalent among patients who will ultimately develop diabetes, and increase the risk of diabetes independently of other known risk factors. The apparent bidirectional relationships suggest that primary prevention of CVD may also help prevent diabetes.
Literature
1.
go back to reference Association AD (2008) Economic costs of diabetes in the U.S. in 2007. Diab Care 31:596–615CrossRef Association AD (2008) Economic costs of diabetes in the U.S. in 2007. Diab Care 31:596–615CrossRef
2.
go back to reference Nichols GA, Arondekar B, Herman WH (2008) Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care 14:791–798PubMed Nichols GA, Arondekar B, Herman WH (2008) Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care 14:791–798PubMed
3.
go back to reference American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diab Care 33:S11–S61CrossRef American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diab Care 33:S11–S61CrossRef
4.
go back to reference Kostis JB, Saunders M (2005) The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 18:731–737CrossRefPubMed Kostis JB, Saunders M (2005) The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 18:731–737CrossRefPubMed
5.
go back to reference Golden SH, Williams JE, Ford DE et al (2004) Depressive symptoms and the risk of type 2 diabetes: the atherosclerosis risk in communities study. Diab Care 27:429–435CrossRef Golden SH, Williams JE, Ford DE et al (2004) Depressive symptoms and the risk of type 2 diabetes: the atherosclerosis risk in communities study. Diab Care 27:429–435CrossRef
6.
go back to reference American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Disorders (2004) Prevention or delay of type 2 diabetes. Diab Care 27(Suppl 1):S47–S54 American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Disorders (2004) Prevention or delay of type 2 diabetes. Diab Care 27(Suppl 1):S47–S54
7.
go back to reference Diabetes Prevention Program Research Group (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diab Care 28:888–894CrossRef Diabetes Prevention Program Research Group (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diab Care 28:888–894CrossRef
8.
go back to reference Lindstrom J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679CrossRefPubMed Lindstrom J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679CrossRefPubMed
9.
go back to reference Diabetes Prevention Program Research Group (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1167–1186 Diabetes Prevention Program Research Group (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1167–1186
10.
go back to reference Li G, Zhang P, Wang J et al (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783–1789CrossRefPubMed Li G, Zhang P, Wang J et al (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783–1789CrossRefPubMed
Metadata
Title
Cardiovascular disease, heart failure, chronic kidney disease and depression independently increase the risk of incident diabetes
Authors
G. A. Nichols
E. J. Moler
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1965-8

Other articles of this Issue 3/2011

Diabetologia 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.